L. Tye

4.3k total citations
43 papers, 1.9k citations indexed

About

L. Tye is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, L. Tye has authored 43 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in L. Tye's work include Lung Cancer Treatments and Mutations (24 papers), Colorectal Cancer Treatments and Studies (17 papers) and Pancreatic and Hepatic Oncology Research (7 papers). L. Tye is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Colorectal Cancer Treatments and Studies (17 papers) and Pancreatic and Hepatic Oncology Research (7 papers). L. Tye collaborates with scholars based in United States, Canada and Italy. L. Tye's co-authors include Richard C. Chao, Mark A. Socinski, Neal J. Meropol, Ramaswamy Govindan, Matthew H. Kulke, Paulina Selaru, Xin Huang, Heinz‐Josef Lenz, Charles M. Baum and Giorgio V. Scagliotti and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

L. Tye

42 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Tye United States	18	1.2k	1.0k	550	489	353	43	1.9k
Lorenzo Antonuzzo Italy	23	1.3k 1.1×	609 0.6×	329 0.6×	404 0.8×	253 0.7×	173	1.9k
Isabel Sevilla Spain	19	951 0.8×	328 0.3×	194 0.4×	551 1.1×	437 1.2×	83	1.4k
Yihebali Chi China	16	1.5k 1.2×	817 0.8×	308 0.6×	255 0.5×	137 0.4×	67	2.0k
Jiří Tomášek Czechia	16	680 0.6×	834 0.8×	524 1.0×	177 0.4×	93 0.3×	61	1.4k
Asuka Tsuya Japan	25	1.3k 1.1×	1.2k 1.2×	416 0.8×	374 0.8×	248 0.7×	59	2.2k
Nicoletta Brega United States	16	825 0.7×	804 0.8×	995 1.8×	130 0.3×	113 0.3×	52	2.1k
Panos Fidias United States	25	1.7k 1.4×	1.8k 1.8×	925 1.7×	170 0.3×	148 0.4×	58	3.0k
Salvatore Artale Italy	18	1.9k 1.5×	648 0.6×	287 0.5×	337 0.7×	211 0.6×	41	2.3k
Atsushi Horiike Japan	28	1.3k 1.1×	1.3k 1.3×	604 1.1×	146 0.3×	86 0.2×	107	2.1k
Yasuhisa Ohde Japan	27	875 0.7×	1.6k 1.5×	356 0.6×	309 0.6×	301 0.9×	160	2.5k

Countries citing papers authored by L. Tye

Since Specialization

Citations

This map shows the geographic impact of L. Tye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Tye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Tye more than expected).

Fields of papers citing papers by L. Tye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Tye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Tye. The network helps show where L. Tye may publish in the future.

Co-authorship network of co-authors of L. Tye

This figure shows the co-authorship network connecting the top 25 collaborators of L. Tye. A scholar is included among the top collaborators of L. Tye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Tye. L. Tye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zurita, Amado J., Mehrdad Khajavi, L. Tye, et al.. (2015). Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. British Journal of Cancer. 112(7). 1199–1205. 36 indexed citations

Shaw, Alice T., Sai‐Hong Ignatius Ou, Yung‐Jue Bang, et al.. (2014). Clinical Activity of Crizotinib in Ros1-Rearranged Non-Small Cell Lung Cancer. Annals of Oncology. 25. iv458–iv458. 7 indexed citations

Ou, S.-H.I., D. Ross Camidge, Gregory J. Riely, et al.. (2013). Crizotinib Treatment in Patients (PTS) with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 24. ix43–ix43. 4 indexed citations

Groen, Harry J.M., Mark A. Socinski, Francesco Grossi, et al.. (2013). A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Annals of Oncology. 24(9). 2382–2389. 47 indexed citations

Michaelson, M. Dror, Andrew X. Zhu, David P. Ryan, et al.. (2013). Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. British Journal of Cancer. 108(7). 1393–1401. 18 indexed citations

Blumenschein, George R., Tudor–Eliade Ciuleanu, Francisco Robert, et al.. (2012). Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study. Journal of Thoracic Oncology. 7(9). 1406–1416. 22 indexed citations

Chow, Laura Q.M., Normand Blais, Derek J. Jonker, et al.. (2011). A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 69(3). 709–722. 11 indexed citations

Groen, Henk, James A. Williams, Feng Gao, et al.. (2010). Biomarker Associations With Survival for Refractory NSCLC Patients Receiving Erlotinib +/- Sunitinib in a Randomized Phase 2 Trial. Data Archiving and Networked Services (DANS). 1 indexed citations

Sweeney, Christopher J., E. Gabriela Chiorean, Claire F. Verschraegen, et al.. (2010). A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 28(29). 4513–4520. 41 indexed citations

10.

Robert, Francisco, Alan Sandler, Joan H. Schiller, et al.. (2009). Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemotherapy and Pharmacology. 66(4). 669–680. 32 indexed citations

11.

Novello, Silvia, Giorgio V. Scagliotti, Rafael Rosell, et al.. (2009). Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. British Journal of Cancer. 101(9). 1543–1548. 110 indexed citations

12.

Scagliotti, Giorgio V., Silvia Novello, Julie R. Brahmer, et al.. (2007). PD3-3-8: A phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S470–S470. 5 indexed citations

13.

Brahmer, Julie R., Ramaswamy Govindan, Silvia Novello, et al.. (2007). Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study. Journal of Clinical Oncology. 25(18_suppl). 7542–7542. 36 indexed citations

14.

Bello, Carlo L., Samuel E. DePrimo, John Smeraglia, et al.. (2006). Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. Journal of Clinical Oncology. 24(18_suppl). 4045–4045. 38 indexed citations

15.

Goss, Paul E., Amit M. Oza, Jean‐Marc Nabholtz, et al.. (2000). Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer. Breast Cancer Research and Treatment. 59(1). 55–68. 18 indexed citations

16.

Goss, Paul E., A. Keith Stewart, Félix Couture, et al.. (1999). Combined Results of Two Phase Il Studies of Taxol (Paclitaxel) in Patients with Relapsed or Refractory Lymphomas. Leukemia & lymphoma. 34(3-4). 295–304. 13 indexed citations

17.

Tye, L., et al.. (1997). Anastrozole: a new selective nonsteroidal aromatase inhibitor.. PubMed. 11(11). 1697–703; discussion 1707. 9 indexed citations

18.

Tye, L. & A.F. Burton. (1980). Competitive interactions between corticosterone and 11-dehydrocorticosterone in binding to receptors in fetal mouse tissues. Life Sciences. 27(1). 15–21. 3 indexed citations

19.

Tye, L. & A.F. Burton. (1980). Variation in the pattern of metabolism of corticosteroids in fetal mouse tissues. Life Sciences. 26(1). 35–39. 12 indexed citations

20.

Tye, L., J.F. Richards, & A.F. Burton. (1978). Corticosteroids, Ornithine Decarboxylase Activity and the Incorporation of Leucine, Uridine, and Thymidine into Mouse Placenta. Pediatric Research. 12(12). 1155–1156. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact